{
    "nctId": "NCT02300363",
    "briefTitle": "DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin",
    "officialTitle": "A Phase 1, Single-center, Open-label, 2-period, Single-sequence, Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose LX4211 on the Pharmacokinetics of Single-dose Rosuvastatin (Crestor\u00ae), a Sensitive Breast Cancer Resistance Protein (BCRP) Substrate, in Healthy Male and Female Subjects",
    "overallStatus": "COMPLETED",
    "conditions": "Healthy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "AUC",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult subjects \u226518 to \u226455 years of age\n* Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm\n* Body mass index (BMI) \u226518 and \u226432 kg/sq m\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of clinically significant physical, laboratory, or ECG findings that, in the opinion of the Investigator and/or Sponsor, may interfere with any aspect of study conduct or interpretation of results\n* Use of any medications or supplements/supratherapeutic doses of vitamins within 14 days prior to the first dose administration and throughout the duration of the study\n* Receipt of any investigational agent or study drug within 30 days prior to Screening\n* Receipt of any protein- or antibody-based therapeutic agents within 3 months prior to Screening\n* Prior exposure to LX4211\n* Use of tobacco, smoking cessation products, or products containing nicotine within 3 months prior to Screening and for the duration of the study\n* History of any serious adverse reaction or hypersensitivity to any inactive component of LX4211 or rosuvastatin\n* Existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of LX4211 or rosuvastatin\n* History of any major surgery within 6 months or anticipated surgery prior to Day\n* History of any clinically significant hypoglycemia or hyperglycemia\n* History of renal disease, or significantly abnormal kidney function test at Screening\n* History of hepatic disease, or significantly abnormal liver function tests at Screening\n* History of any clinically relevant psychiatric, renal, hepatic, pancreatic, endocrine, cardiovascular, neurological, hematological, or GI abnormality\n* History of any active infection within 14 days prior to Day 1\n* History of alcohol or substance abuse within 2 years prior to Screening\n* Positive hepatitis panel\n* Donation or loss of \\>500 mL of blood or blood product within 3 months prior to Screening\n* Women who are breastfeeding or are planning to become pregnant during the study, or women who have a positive serum pregnancy test\n* Positive urine glucose at Screening\n* Positive urine screen for drugs of abuse and cotinine at Screening, Day -1, or Day 13\n* Inability or difficulty swallowing whole tablets\n* Unable or unwilling to cooperate with the Investigator for any reason",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}